Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 17 |
| List of Tables | 15 | 3 |
| List of Figures | 18 | 1 |
| Introduction | 19 | 1 |
| Global Markets Direct Report Coverage | 19 | 1 |
| Peritoneal Cancer Overview | 20 | 1 |
| Therapeutics Development | 21 | 2 |
| Pipeline Products for Peritoneal Cancer Overview | 21 | 1 |
| Pipeline Products for Peritoneal Cancer Comparative Analysis | 22 | 1 |
| Peritoneal Cancer Therapeutics under Development by Companies | 23 | 7 |
| Peritoneal Cancer Therapeutics under Investigation by Universities/Institutes | 30 | 1 |
| Peritoneal Cancer Pipeline Products Glance | 31 | 4 |
| Late Stage Products | 31 | 1 |
| Clinical Stage Products | 32 | 1 |
| Early Stage Products | 33 | 1 |
| Unknown Stage Products | 34 | 1 |
| Peritoneal Cancer Products under Development by Companies | 35 | 7 |
| Peritoneal Cancer Products under Investigation by Universities/Institutes | 42 | 1 |
| Peritoneal Cancer Companies Involved in Therapeutics Development | 43 | 81 |
| AbbVie Inc | 43 | 1 |
| Acetylon Pharmaceuticals, Inc. | 44 | 1 |
| Adaptimmune Therapeutics Plc | 45 | 1 |
| Aduro BioTech, Inc. | 46 | 1 |
| Advanced Accelerator Applications S.A. | 47 | 1 |
| Advenchen Laboratories, LLC | 48 | 1 |
| Amgen Inc. | 49 | 1 |
| Astex Pharmaceuticals, Inc. | 50 | 1 |
| AstraZeneca Plc | 51 | 1 |
| Atara Biotherapeutics, Inc. | 52 | 1 |
| AVEO Pharmaceuticals, Inc. | 53 | 1 |
| Bayer AG | 54 | 1 |
| Boehringer Ingelheim GmbH | 55 | 1 |
| Boston Biomedical, Inc. | 56 | 1 |
| Celldex Therapeutics, Inc. | 57 | 1 |
| Celsion Corporation | 58 | 1 |
| CerRx, Inc. | 59 | 1 |
| Cerulean Pharma, Inc. | 60 | 1 |
| Clovis Oncology, Inc. | 61 | 1 |
| Critical Outcome Technologies Inc. | 62 | 1 |
| CritiTech, Inc. | 63 | 1 |
| CTI BioPharma Corp. | 64 | 1 |
| Dr. Reddy's Laboratories Limited | 65 | 1 |
| EirGenix Inc. | 66 | 1 |
| Eisai Co., Ltd. | 67 | 1 |
| Eli Lilly and Company | 68 | 1 |
| Esperance Pharmaceuticals, Inc. | 69 | 1 |
| Exelixis, Inc. | 70 | 1 |
| F. Hoffmann-La Roche Ltd. | 71 | 1 |
| Galena Biopharma, Inc. | 72 | 1 |
| Ganymed Pharmaceuticals AG | 73 | 1 |
| Gene Techno Science Co., Ltd. | 74 | 1 |
| Genelux Corporation | 75 | 1 |
| Genentech, Inc. | 76 | 1 |
| Genor BioPharma Co., Ltd. | 77 | 1 |
| Glycotope GmbH | 78 | 1 |
| Gradalis Inc. | 79 | 1 |
| Hemispherx Biopharma, Inc. | 80 | 1 |
| ImmunoGen, Inc. | 81 | 1 |
| Immunovaccine, Inc. | 82 | 1 |
| Incyte Corporation | 83 | 1 |
| Innate Pharma S.A. | 84 | 1 |
| Johnson &Johnson | 85 | 1 |
| Juno Therapeutics Inc. | 86 | 1 |
| Kyowa Hakko Kirin Co., Ltd. | 87 | 1 |
| Lee's Pharmaceutical Holdings Limited | 88 | 1 |
| Mabion SA | 89 | 1 |
| MabVax Therapeutics Holdings, Inc. | 90 | 1 |
| Mateon Therapeutics Inc | 91 | 1 |
| MedImmune, LLC | 92 | 1 |
| Medivation, Inc. | 93 | 1 |
| Merck &Co., Inc. | 94 | 1 |
| Merck KGaA | 95 | 1 |
| Merrimack Pharmaceuticals, Inc. | 96 | 1 |
| Millennium Pharmaceuticals Inc | 97 | 1 |
| MolMed S.p.A. | 98 | 1 |
| Mycenax Biotech Inc. | 99 | 1 |
| Neopharm Ltd. | 100 | 1 |
| Novartis AG | 101 | 1 |
| OBI Pharma, Inc. | 102 | 1 |
| Oncobiologics, Inc. | 103 | 1 |
| Oncolix, Inc. | 104 | 1 |
| Oncolytics Biotech Inc. | 105 | 1 |
| OncoMed Pharmaceuticals, Inc. | 106 | 1 |
| Ono Pharmaceutical Co., Ltd. | 107 | 1 |
| Oxford BioMedica Plc | 108 | 1 |
| Pharma Mar, S.A. | 109 | 1 |
| PsiOxus Therapeutics Limited | 110 | 1 |
| Quest PharmaTech Inc. | 111 | 1 |
| Richter Gedeon Nyrt. | 112 | 1 |
| Samyang Holdings Corporation | 113 | 1 |
| Sanofi Pasteur SA | 114 | 1 |
| Sotio a.s. | 115 | 1 |
| TapImmune Inc. | 116 | 1 |
| Tara Immuno-Oncology Therapeutics LLC | 117 | 1 |
| Tesaro, Inc. | 118 | 1 |
| TetraLogic Pharmaceuticals | 119 | 1 |
| Tyrogenex, Inc. | 120 | 1 |
| Vascular Biogenics Ltd. | 121 | 1 |
| VentiRx Pharmaceuticals, Inc. | 122 | 1 |
| Vyriad | 123 | 1 |
| Peritoneal Cancer Therapeutics Assessment | 124 | 26 |
| Assessment by Monotherapy Products | 124 | 1 |
| Assessment by Target | 125 | 10 |
| Assessment by Mechanism of Action | 135 | 11 |
| Assessment by Route of Administration | 146 | 2 |
| Assessment by Molecule Type | 148 | 2 |
| Drug Profiles | 150 | 514 |
| Pb-TCMC-Trastuzumab Drug Profile | 150 | 2 |
| abiraterone acetate Drug Profile | 152 | 5 |
| ABT-767 Drug Profile | 157 | 1 |
| acalabrutinib Drug Profile | 158 | 3 |
| adagloxad simolenin Drug Profile | 161 | 2 |
| afuresertib hydrochloride Drug Profile | 163 | 3 |
| AL-3818 Drug Profile | 166 | 3 |
| amcasertib Drug Profile | 169 | 2 |
| anetumab ravtansine Drug Profile | 171 | 3 |
| atezolizumab Drug Profile | 174 | 13 |
| AV-203 Drug Profile | 187 | 3 |
| avelumab Drug Profile | 190 | 5 |
| AZD-1775 Drug Profile | 195 | 3 |
| AZD-5363 Drug Profile | 198 | 3 |
| bevacizumab biosimilar Drug Profile | 201 | 2 |
| bevacizumab biosimilar Drug Profile | 203 | 1 |
| bevacizumab biosimilar Drug Profile | 204 | 1 |
| bevacizumab biosimilar Drug Profile | 205 | 1 |
| bevacizumab biosimilar Drug Profile | 206 | 1 |
| bevacizumab biosimilar Drug Profile | 207 | 1 |
| bevacizumab biosimilar Drug Profile | 208 | 1 |
| bevacizumab biosimilar Drug Profile | 209 | 1 |
| bevacizumab biosimilar Drug Profile | 210 | 1 |
| bevacizumab biosimilar Drug Profile | 211 | 1 |
| birinapant Drug Profile | 212 | 7 |
| cabozantinib s-malate Drug Profile | 219 | 18 |
| catumaxomab Drug Profile | 237 | 2 |
| CDX-1401 Drug Profile | 239 | 3 |
| cediranib maleate Drug Profile | 242 | 3 |
| Cellular Immunotherapy for Oncology Drug Profile | 245 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 246 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 247 | 1 |
| Cellular Immunotherapy for Ovarian, Peritoneal and Fallopian Tube Cancer Drug Profile | 248 | 1 |
| Cellular Immunotherapy to Target WT1 for Oncology Drug Profile | 249 | 2 |
| COTI-2 Drug Profile | 251 | 8 |
| CRLX-101 Drug Profile | 259 | 11 |
| CRS-207 Drug Profile | 270 | 6 |
| DCVAC/OvCa Drug Profile | 276 | 1 |
| demcizumab Drug Profile | 277 | 8 |
| DMUC-4064A Drug Profile | 285 | 1 |
| DPX-Survivac Drug Profile | 286 | 8 |
| enadenotucirev Drug Profile | 294 | 4 |
| EP-100 Drug Profile | 298 | 2 |
| epacadostat Drug Profile | 300 | 5 |
| everolimus Drug Profile | 305 | 12 |
| fenretinide Drug Profile | 317 | 2 |
| fosbretabulin tromethamine Drug Profile | 319 | 9 |
| GALE-301 Drug Profile | 328 | 5 |
| ganetespib Drug Profile | 333 | 12 |
| gemogenovatucel-T Drug Profile | 345 | 4 |
| GEN-1 Drug Profile | 349 | 6 |
| gimatecan Drug Profile | 355 | 1 |
| GLONC-1 Drug Profile | 356 | 4 |
| GLV-1h153 Drug Profile | 360 | 1 |
| GSK-3377794 Drug Profile | 361 | 6 |
| guadecitabine Drug Profile | 367 | 7 |
| IMAB-027 Drug Profile | 374 | 1 |
| ipafricept Drug Profile | 375 | 4 |
| JCAR-020 Drug Profile | 379 | 2 |
| LCL-161 Drug Profile | 381 | 2 |
| lenvatinib mesylate Drug Profile | 383 | 11 |
| lurbinectedin Drug Profile | 394 | 6 |
| MesoCART Drug Profile | 400 | 1 |
| mirvetuximab soravtansine Drug Profile | 401 | 4 |
| MK-2206 Drug Profile | 405 | 3 |
| monalizumab Drug Profile | 408 | 3 |
| Monoclonal Antibody Conjugate to Target B7-H3 for Oncology Drug Profile | 411 | 1 |
| motolimod Drug Profile | 412 | 3 |
| NGR-hTNF Drug Profile | 415 | 5 |
| nintedanib Drug Profile | 420 | 9 |
| niraparib Drug Profile | 429 | 4 |
| nivolumab Drug Profile | 433 | 30 |
| NSC-748933 Drug Profile | 463 | 2 |
| ofranergene obadenovec Drug Profile | 465 | 6 |
| Oncolytic Virus to Target Carcinoembryonic Antigen for Oncology Drug Profile | 471 | 1 |
| Oncolytic Virus to Target CD46 for Oncology Drug Profile | 472 | 1 |
| oregovomab Drug Profile | 473 | 2 |
| OXB-301 Drug Profile | 475 | 3 |
| paclitaxel Drug Profile | 478 | 4 |
| paclitaxel Drug Profile | 482 | 1 |
| paclitaxel poliglumex Drug Profile | 483 | 4 |
| PankoMab-GEX Drug Profile | 487 | 2 |
| pazopanib hydrochloride Drug Profile | 489 | 7 |
| pelareorep Drug Profile | 496 | 14 |
| pembrolizumab Drug Profile | 510 | 32 |
| pertuzumab Drug Profile | 542 | 5 |
| prexasertib Drug Profile | 547 | 2 |
| Prolanta Drug Profile | 549 | 2 |
| ralimetinib mesylate Drug Profile | 551 | 1 |
| ramucirumab Drug Profile | 552 | 8 |
| regorafenib Drug Profile | 560 | 10 |
| ricolinostat Drug Profile | 570 | 7 |
| rintatolimod Drug Profile | 577 | 9 |
| rucaparib camsylate Drug Profile | 586 | 7 |
| sapanisertib Drug Profile | 593 | 3 |
| selumetinib sulfate Drug Profile | 596 | 5 |
| seribantumab Drug Profile | 601 | 7 |
| sonidegib phosphate Drug Profile | 608 | 4 |
| STM-434 Drug Profile | 612 | 2 |
| talazoparib Drug Profile | 614 | 6 |
| Theranean Drug Profile | 620 | 1 |
| tivozanib hydrochloride Drug Profile | 621 | 10 |
| TPIV-200 Drug Profile | 631 | 3 |
| trabectedin Drug Profile | 634 | 7 |
| trebananib Drug Profile | 641 | 4 |
| tremelimumab Drug Profile | 645 | 4 |
| Vaccine for Oncology Drug Profile | 649 | 1 |
| Vaccine to Target Cellular Tumor Antigen p53 for Oncology Drug Profile | 650 | 1 |
| vanucizumab Drug Profile | 651 | 2 |
| VCP-2292 Drug Profile | 653 | 1 |
| veliparib Drug Profile | 654 | 6 |
| vistusertib Drug Profile | 660 | 2 |
| X-82 Drug Profile | 662 | 2 |
| Peritoneal Cancer Dormant Projects | 664 | 5 |
| Peritoneal Cancer Discontinued Products | 669 | 1 |
| Peritoneal Cancer Product Development Milestones | 670 | 5 |
| Featured News &Press Releases | 670 | 1 |
| Jul 19, 2016: Cerulean Receives FDA Fast Track Designation for CRLX101 for the Treatment of Platinum-Resistant Ovarian Cancer | 670 | 1 |
| May 14, 2015: PharmaMar announces new advances in oncology at ASCO 2015 for its compound YONDELIS in small cell lung cancer, soft tissue sarcoma, and mesothelioma | 670 | 1 |
| May 13, 2015: TESARO Announces Abstracts To Be Presented On Niraparib at the 2015 American Society of Clinical Oncology Annual Meeting | 671 | 1 |
| Mar 03, 2015: Oncolytics Biotech Announces Receipt of Orphan Drug Designation from the U.S. FDA for Primary Peritoneal Cancer | 672 | 1 |
| Mar 02, 2015: Oncolytics Biotech Announces Receipt of Orphan Drug Designation from the U.S. FDA for Cancer of the Fallopian Tube | 672 | 1 |
| Sep 22, 2014: AbbVie to Present Clinical Study Data on Potential New Oncology Medicine at the 2014 European Society of Medical Oncology Annual Meeting | 673 | 1 |
| Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer | 673 | 1 |
| Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group | 674 | 1 |
| Appendix | 675 | 2 |
| Methodology | 675 | 1 |
| Coverage | 675 | 1 |
| Secondary Research | 675 | 1 |
| Primary Research | 675 | 1 |
| Expert Panel Validation | 675 | 1 |
| Contact Us | 675 | 1 |
| Disclaimer | 676 | 1 |